Patients were followed for clinical toxicities, alterations in model for end-stage-lier disease (MELD) score, tumor response, downstaging to RFA, resection, transplantation, and surial.

• 随访观察患者的临床毒性，晚期肝脏疾病模型(MELD)评分变化，肿瘤反应，争取降期可射频消融(RFA)，切除，肝移植和存活率。